In an article titled “Bevacizumab plus fosbretabulin improves survival in ovarian cancer” (published November 10, 2014,) the headline did not clearly state that drug combination improves progression free survival. It does not improve overall survival.

Ads

You May Also Like

Extended anticoagulant therapy reduced risk of VTE recurrence

Apixaban was the safest anticoagulant used for extended treatment of venous thromboembolism (VTE), according ...